Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| CytomX Therapeutics Inc. | Praluzatamab ravtansine (CX-2009) | Breast cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Daiichi Sankyo Co., Ltd. ADR | DATROWAY (datopotamab deruxtecan) - (TROPION-Lung17) | Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Ongoing | Intravenous | Oncology |
| Daiichi Sankyo Co., Ltd. ADR | Raludotatug deruxtecan (DS-6000, R-DXd) - (REJOICE-Ovarian01) | Ovarian cancer | Phase 2/3 | Enrollment Initiation | Intravenous | Oncology |
| Dare Bioscience Inc. | Ovaprene | Contraception | Phase 3 | Data Released | Vaginal | Women's Health |
| Dare Bioscience Inc. | Sildenafil Cream, 3.6% - (RESPOND) | Female Sexual Arousal Disorder (FSAD) | Phase 3 | Trial Planned | Topical | Women's Health |
| Day One Biopharmaceuticals Inc. | DAY101 - (FIRELIGHT-1) | RAF-altered solid tumors | Phase 2 | Trial Discontinued | Oral | Oncology |
| Day One Biopharmaceuticals Inc. | Upifitamab Rilsodotin (UpRi) - (UP-NEXT) | Ovarian Cancer | Phase 3 | Clinical Hold | Intravenous | Oncology |
| Day One Biopharmaceuticals Inc. | DAY101 - (FIREFLY-2) | Pediatric Low-Grade Glioma (pLGG) | Phase 3 | Ongoing | Oral | Oncology |
